Glioma Panel 1 near me in Thane

The Glioma Panel 1 is a streamlined and clinically impactful diagnostic package designed to support accurate classification, prognosis, and treatment decision-making in patients with gliomas. This package integrates IDH1 and IDH2 mutation analysis, which is fundamental to contemporary glioma classification and provides essential prognostic insight regarding tumor biology and patient outcomes. It further assesses 1p/19q co-deletion status, a defining molecular marker for oligodendrogliomas that guides both diagnostic accuracy and therapeutic strategy. In addition, the package includes MGMT promoter methylation testing, a critical predictive biomarker for response to alkylating chemotherapy, helping clinicians anticipate treatment benefit and tailor therapy accordingly. By combining these key molecular markers, the package delivers a focused, clinically actionable profile aligned with current WHO tumor classification standards. Getting tested with the Glioma Panel 1 empowers clinicians to make informed, evidence-based treatment decisions, ensuring patients receive the most effective, personalized, and precise care in the management of gliomas.

Note: One representative block of the tumor is required. However, 1-4 representative blocks of tumors are acceptable.

Disclaimer: In no event shall the liability of TATA 1MG exceed the amount of actual cost of test charges incurred by the customer as stated on the invoice issued by Tata 1mg.